TABLE 4.

Results of linear mixed model analyses Including baseline values of all scalable plasma and TabCAT-BHA markers as predictors, demographic and clinical covariates, and Clinical Dementia Rating Scale (CDR) Sum of Boxes as an outcome (n = 185; 32 SCI, 107 MCI, 46 dementia).

	β	SE	df	P
Baseline plasma Aβ42/40 × Years since baseline	2.060	5.937	99	0.729
Baseline plasma pTau181 × Years since baseline	0.357	0.082	103	<0.001
Baseline plasma NfL × Years since baseline	0.018	0.004	90	<0.001
Baseline plasma GFAP × Years since baseline	−0.002	0.001	125	0.029
Baseline TabCAT-BHA × Years since baseline	−0.320	0.047	120	<0.001
Baseline plasma Aβ42/40	−0.122	8.433	159	0.149
Baseline plasma pTau181	−0.128	0.117	162	0.274
Baseline plasma NfL	−0.001	0.006	157	0.876
Baseline plasma GFAP	−0.001	0.001	165	0.658
Baseline TabCAT-BHA	−0.283	0.081	166	<0.001
Age (years; centered)	0.012	0.014	163	0.397
Sex (female)	0.163	0.228	164	0.476
Education (years)	0.025	0.037	165	0.500
APOE ε4 allele	0.209	0.251	166	0.408
Baseline dementia diagnosis (reference)	-	-	-	-
Baseline MCI diagnosis	−3.487	0.302	165	<0.001
Baseline SCI diagnosis	−4.832	0.431	164	<0.001
Years since baseline	−0.940	0.477	96	0.052

Abbreviations: Aβ, amyloid β; APOE, apolipoprotein E; df, degrees of freedom; GFAP, glial fibrillary acidic protein; MCI, mild cognitive impairment; NfL, neurofilament light; SCI, subjective cognitive impairment; SE, standard error; TabCAT-BHA, Tablet-based Cognitive Assessment Tool Brain Health Assessment. Degrees of freedom are estimated using Satterthwaite's method.